文献速递消化系统肿瘤

斯巴达利珠单抗联合FLOT围手术治疗可切除胃癌的GASPAR 2期研究

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study.
PubMed 文献 · Eur J Cancer · 2026-01-30

GASPAR是一项多中心单臂Simon两阶段2期试验,评估斯巴达利珠单抗联合FLOT围手术期治疗可切除胃或胃食管交界腺癌的疗效与安全性。共纳入68例患者,64例可评估疗效者中pCR率31%,主要病理缓解率50%,2年OS率86%、DFS率77.5%,安全性可接受。

要点

  • 斯巴达利珠单抗联合FLOT围手术期治疗可切除胃癌pCR率达31%。
  • 主要病理缓解率为50%,2年OS率86%、DFS率77.5%。
  • 3级免疫相关不良事件见于5例,出现1例肺孢子菌相关死亡。

核心结论

  • 斯巴达利珠单抗联合FLOT作为可切除胃癌围手术期治疗显示出高效低毒的特点。

研究设计与样本

  • GASPAR为多中心单臂Simon两阶段2期试验,计划需67例患者(H0/H1=10/23%,α=5%,β=20%)。
  • 实际纳入68例未治疗的可切除局限期胃或胃食管交界腺癌患者(≥cT2或cN+)。
  • 患者接受4周期术前和术后FLOT联合2周期术前和术后斯巴达利珠单抗治疗。
  • 主要终点为按Becker标准评估的病理完全缓解(pCR)率。

主要发现

  • 68例患者中男性78%,中位年龄63岁(范围31-79),cT3占51%,胃食管交界占60%,cN+占58%。
  • 67例开始治疗,因毒性延迟FLOT给药14例(21%),剂量降低28例(42%)。
  • 手术患者中R0切除62例(95%)。
  • 64例可评估疗效患者中,pCR 20例(31%),主要病理缓解12例(19%),主要缓解率50%。
  • 中位随访30个月(范围4-42),2年OS率86%[77.8-94.9],DFS率77.5%[68.1-88.2]。

临床怎么用

  • 该联合方案可作为可切除胃癌围手术期治疗的潜在选择,但需关注免疫相关不良事件及术后并发症。

局限性

  • 单臂设计缺乏对照,样本量有限,结论需随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Perioperative chemotherapy with FLOT is a standard of care for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. This trial evaluated the anti-PD-1 monoclonal antibody spartalizumab combined with FLOT as perioperative treatment for resectable patients. PATIENTS AND METHODS: GASPAR is a multicenter, single-arm, Simon two-stage phase 2 trial. Patients with untreated localized gastric or GEJ adenocarcinoma considered resectable (≥ cT2 or cN+) received 4 pre- and post-operative cycles of FLOT and 2 pre- and post-operative cycles of spartalizumab. The main endpoint was the rate of pathological complete regression (pCR) according to the Becker criteria, requiring 67 patients (H0/H1 =10/23 %, α=5 %, β=20 %). RESULTS: Overall, 68 patients were included: men (78 %), median age 63 years [range 31-79], cT3 51 %, GEJ 60 %, cN+ 58 %. Treatment was started in 67 patients. Delayed FLOT administration for toxicity and dose reduction concerned 14 (21 %) and 28 (42 %) patients, respectively. Surgery was R0 in 62 (95 %) of the patients operated on. Among 64 patients assessable for efficacy, pCR was observed in 20 patients (31 %), and major pathological response in 12 patients (19 %), meaning a major response rate of 50 %. Five patients developed grade 3 immune-mediated adverse events. One death related to pneumocystis occurred. Severe post-surgery complications occurred in 15 patients (23 %). After a median follow-up of 30 months [range 4-42], OS and DFS at 2 years were 86 % [77.8-94.9] and 77.5 % [68.1-88.2], respectively. CONCLUSIONS: Spartalizumab combined with FLOT shows high efficacy as perioperative treatment in patients with resectable gastric cancer, and an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04736485.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dos Santos M, Lequesne J, Piessen G, et al. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study. Eur J Cancer. 2026. PMID: 41653501. doi:10.1016/j.ejca.2026.116258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。